Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Astrakhan/3212/2020 Like (H5N8) Virus Vaccine With AS03 Adjuvant System in Medically Stable Adults
A legfontosabb adatok
- Ki végzi
- GlaxoSmithKline
- Hol
- Anderson, Anniston, Austin, Boerne, Chamblee, Chula Vista, El Dorado, Knoxville, Lenexa, Lexington, Long Beach, Meridian, Metairie, Mobile, Norfolk, Pembroke Pines, San Antonio, Santa Ana, Tempe és Tomball (Egyesült Államok)Mind a 20 helyszín megnézése
- Azonosító
- Állapot
- Befejeződött
- Fázis
- 1/2. fázis
- Résztvevők
- 518 fő vett részt
- Kezdés
- 2023. aug. 3.
- Befejezés
- 2024. szept. 19.
- A vizsgálat típusa
- Beavatkozással járó, 8 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- FLU Q-PAN H5N8 375_B
- FLU Q-PAN H5N8 375_A
- FLU Q-PAN H5N8 750_B
- FLU Q-PAN H5N8 750_A
- A regiszteradat frissítve
- 2025. augusztus 19.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Részt vehetnek
A regiszter feltételei, szó szerint
Mind a 28 feltétel megnézéseKevesebb
Ki vehet részt
- Medically stable participants as established by medical history and clinical examination before entering into the study
- A male or female >=18 years of age at the time of signing consent form
- Participants, who, in the opinion of the investigator, can and will comply with the requirements of the protocol
- Written or witnessed/thumb printed informed consent obtained from the participant prior to performance of any study specific procedure
- Female participants of childbearing potential or non-childbearing potential may be enrolled in the study if specific criteria are met
Ki nem vehet részt
- Use of any investigational or non-registered product other than the study vaccine during the period beginning 30 days before the first dose of study vaccine (Day -29 to Day 1), or planned use during the entire study period
- Use of public health emergency vaccines like coronavirus disease 2019 (COVID-19), Monkey pox (mpox) etc. These can be given at any time, but there should a gap of 2 - weeks before a dose of study vaccine can be given
- Use of any licensed vaccines: prior to receipt of the study vaccine and continuing up to 3 weeks after receiving the dose 2 of study vaccine
- Administration of long-acting immune-modifying drugs at any time during the study period
- Administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 3 months before the first dose of study vaccine or planned administration during the study period
- Chronic administration of immunosuppressants or other immune-modifying drugs during the period starting 3 months prior to the first vaccine dose and through the entire study period. For corticosteroids, this will mean prednisone equivalent >=20 milligrams/day for 14 days or a total of >=280 mg of prednisone equivalent dose in any 14-day period. Inhaled and topical steroids are allowed
- Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non investigational vaccine/product
- Current diagnosis or history of autoimmune disorder(s) except hypothyroidism due to Hashimoto's thyroiditis
- History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine
- Clinically significant acute or chronic pulmonary, cardiovascular, hepatic, or renal disease that appears uncontrolled or untreated, as determined by history or physical examination
- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history, physical examination, or abnormalities in screening blood tests
- Recurrent history of or uncontrolled neurological disorders or seizures
- History of Guillain-Barré syndrome
- Diagnosed with cancer, or treatment for cancer within 3 years; Persons with a history of cancer who are disease-free without treatment for 3 years or more are eligible; Persons with a history of histologically confirmed basal cell carcinoma of the skin successfully treated with local excision only, are accepted and are eligible, but other histologic types of skin cancer are exclusionary; Women who are disease-free 3 years or more after treatment for breast cancer and receiving long-term prophylaxis are eligible
- Personal or family history of narcolepsy
- Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study
- History of/or current drug/alcohol abuse
- Food and Drug Administration (FDA) toxicity Grade 2, or greater, laboratory tests at Screening
- Documented human immunodeficiency virus-positive participants
- Bedridden participants
- Pregnant or lactating female
- Female planning to become pregnant or planning to discontinue contraceptive precautions within 2 months after completion of the vaccination series
- Any study personnel or their immediate dependents, family, or household member
Helyszínek itt: Egyesült Államok
- Anderson, South CarolinaHospital not named in the registry
- Anniston, AlabamaHospital not named in the registry
- Austin, TexasHospital not named in the registry
- Boerne, TexasHospital not named in the registry
- Chamblee, GeorgiaHospital not named in the registry
- Chula Vista, CaliforniaHospital not named in the registry
- El Dorado, KansasHospital not named in the registry
- Knoxville, TennesseeHospital not named in the registry
- Lenexa, KansasHospital not named in the registry
- Lexington, KentuckyHospital not named in the registry
- Long Beach, CaliforniaHospital not named in the registry
- Meridian, IdahoHospital not named in the registry
- Metairie, LouisianaHospital not named in the registry
- Mobile, AlabamaHospital not named in the registry
- Norfolk, VirginiaHospital not named in the registry
- Pembroke Pines, FloridaHospital not named in the registry
- San Antonio, TexasHospital not named in the registry
- Santa Ana, CaliforniaHospital not named in the registry
- Tempe, ArizonaHospital not named in the registry
- Tomball, TexasHospital not named in the registry
A vizsgálatról
Mit akar kideríteni a vizsgálat
The purpose of this study is to assess the safety and immunogenicity of different formulations of monovalent Influenza A/Astrakhan/3212/2020-like virus vaccine with AS03 adjuvant system in adults greater than or equal to (>=)18 years of age.
A vizsgálat 8 csoportja
- Age group 18-64: FLU Q-PAN H5N8 375_BMár használt kezelés, összehasonlításként
Participants received 2 doses of 375\_B vaccine formulation, 21 days apart.
Kezelés: FLU Q-PAN H5N8 375_B
- Age group 18-64: FLU Q-PAN H5N8 375_AMár használt kezelés, összehasonlításként
Participants received 2 doses of 375\_A vaccine formulation, 21 days apart.
Kezelés: FLU Q-PAN H5N8 375_A
- Age group 18-64: FLU Q-PAN H5N8 750_BMár használt kezelés, összehasonlításként
Participants received 2 doses of 750\_B vaccine formulation, 21 days apart.
Kezelés: FLU Q-PAN H5N8 750_B
- Age group 18-64: FLU Q-PAN H5N8 750_AMár használt kezelés, összehasonlításként
Participants received 2 doses of 750\_A vaccine formulation, 21 days apart.
Kezelés: FLU Q-PAN H5N8 750_A
- Age group >=65: FLU Q-PAN H5N8 375_BMár használt kezelés, összehasonlításként
Participants received 2 doses of 375\_B vaccine formulation, 21 days apart.
Kezelés: FLU Q-PAN H5N8 375_B
- Age group >=65: FLU Q-PAN H5N8 375_AMár használt kezelés, összehasonlításként
Participants received 2 doses of 375\_A vaccine formulation, 21 days apart.
Kezelés: FLU Q-PAN H5N8 375_A
- Age group >=65: FLU Q-PAN H5N8 750_BMár használt kezelés, összehasonlításként
Participants received 2 doses of 750\_B vaccine formulation, 21 days apart.
Kezelés: FLU Q-PAN H5N8 750_B
- Age group >=65: FLU Q-PAN H5N8 750_AMár használt kezelés, összehasonlításként
Participants received 2 doses of 750\_A vaccine formulation, 21 days apart.
Kezelés: FLU Q-PAN H5N8 750_A
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Phase I/II Observer-blind, Randomized, Multi-center Trial to Evaluate the Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Astrakhan/3212/2020 Like (H5N8) Virus Vaccine With AS03 Adjuvant System (Referred to as Q-Pan H5N8), Given as a Two-dose Series to Adults 18 to 64 Years of Age and 65 Years of Age and Older
- Publikációk
- Immunogenicity and safety of AS03-adjuvanted A/Astrakhan/3212/2020 (H5N8)-like influenza vaccine in adults: Phase 1/2, observer-blinded, randomized trial.Human vaccines & immunotherapeutics, 2026
- A regiszteradat frissítve
- 2025. augusztus 19.